Standard Timing for Checking Lithium Levels
Lithium serum trough levels should be drawn 12 hours after the last dose for patients on standard or twice-daily dosing regimens, and 24 hours after the last dose for patients taking once-daily extended-release formulations. 1
Timing Based on Formulation
The critical distinction lies in the lithium formulation being used:
Standard/Immediate-Release Formulations
- Draw blood 12 hours after the last dose 1, 2, 3
- This timing applies to lithium carbonate given 2-3 times daily
- Peak plasma concentration occurs at 1-2 hours for standard-release forms 2
- The 12-hour standardized timing allows comparison with decades of published lithium dosing data 4
Extended-Release Formulations (Once-Daily Dosing)
- Draw blood 24 hours after the last dose 5
- Peak plasma concentration occurs at 4-5 hours for sustained-release forms 2
- Drawing at 12 hours with once-daily dosing yields levels approximately 1.3 times higher than true trough levels 5
- This can result in patients being maintained on inappropriately low doses if clinicians use the 12-hour standard 5
Important caveat: If using extended-release formulations with twice-daily dosing, the 12-hour timing remains appropriate, as blood levels at 12 hours are essentially identical between immediate and extended-release formulations 4
Monitoring Frequency
The frequency of monitoring varies by treatment phase:
Acute Phase (Initial Stabilization)
- Check levels twice weekly until serum level and clinical condition stabilize 1, 6
- Continue frequent monitoring during any dose adjustments 7
Maintenance Phase
- Check levels every 2 months minimum in uncomplicated cases during remission 1
- Check every 3-6 months along with renal function, thyroid function, and electrolytes 6, 7
- More frequent monitoring required if:
Critical Monitoring Considerations
Therapeutic Range
- Acute mania: 1.0-1.5 mEq/L 1
- Maintenance therapy: 0.6-1.2 mEq/L 1
- Some guidelines suggest 0.6-0.8 mmol/L, particularly for elderly patients 2
Special Populations
Elderly patients (≥60 years):
- Often require reduced dosages 1
- May exhibit toxicity at levels ordinarily tolerated by younger patients 1
- Consider lower therapeutic range (0.4-0.7 mmol/L for those ≥80 years) 8
Patients with renal impairment:
- Renal insufficiency is a relative contraindication 2
- Requires more frequent monitoring of GFR, electrolytes, and lithium levels 7
- Lithium is nephrotoxic and may cause renal tubular dysfunction even at therapeutic levels 7
Drug Interactions Requiring Enhanced Monitoring
Close monitoring is essential when lithium is combined with:
- Diuretics (increase lithium retention) 9
- ACE inhibitors/ARBs (increase lithium toxicity risk) 9
- NSAIDs (reduce lithium clearance) 7
- Eplerenone or other potassium-sparing agents (avoid combination if possible; if unavoidable, monitor plasma lithium closely) 9
Common Pitfall
Do not rely solely on serum levels. Accurate patient evaluation requires both clinical assessment and laboratory analysis 1. Lithium toxicity can occur at therapeutic levels, particularly with chronic use 7, and clinical signs must be monitored alongside laboratory values.
During Intercurrent Illness
Temporarily discontinue lithium in patients with serious intercurrent illness that increases AKI risk 7, 10, and maintain hydration during any illness 7.